Nicox has initiated a phase 2b clinical trial to evaluate NCX 4251 vs. placebo in patients with acute exacerbations of blepharitis, according to a press release.
NCX 4251 (fluticasone propionate nanocrystal ophthalmic suspension) is applied to the eyelids to target the area of inflammation while minimizing intraocular exposure to fluticasone and the risk for developing increased IOP or cataract.
In the Mississippi trial, 200 patients will be randomly assigned to once-daily NCX 4251 0.1% or placebo at up to 10 U.S. sites. The primary endpoint is the proportion of patients (Read more...)
Uncategorized